Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 37
Filtrer
1.
Cureus ; 16(1): e51856, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-38327974

RÉSUMÉ

In this case, we explore the diagnostic workup of a patient presenting with symptomatic hypercalcemia. Initially suspected to have multiple myeloma, the diagnostic evaluation instead unveiled non-germinal center (non-GC) diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common histologic subtype of non-Hodgkin lymphoma and is heterogeneous in terms of presentation, genetic drivers, and morphology. As primary bone DLBCL is exceedingly rare, the case presented proved to be a diagnostic challenge. The patient presented with one week of weakness, one to two days of nausea, and leg pain. On admission, hypercalcemia, renal failure, anemia, and lytic bone lesions were present and suggestive of multiple myeloma. However, serum protein electrophoresis and immunoglobulin levels did not fit the 2016 World Health Organization (WHO) diagnostic criteria for multiple myeloma. A negative bone marrow biopsy also argued against a diffuse plasma cell neoplasm. Finally, a biopsy from another bone lesion was diagnostic of DLBCL. This case discusses an unusual presentation of DLBCL.

2.
Am J Clin Pathol ; 158(4): 456-471, 2022 10 06.
Article de Anglais | MEDLINE | ID: mdl-35929508

RÉSUMÉ

OBJECTIVES: Mature T-cell neoplasms are a challenging area of diagnostic hematopathology. Flow cytometry has emerged as a useful technique for T-cell assessment. METHODS: We discuss the application of flow cytometry to the evaluation of mature T-cell proliferations, to include illustrative cases, theoretical framework, detailed review of normal and reactive T-cell subsets, and examination of diagnostic pitfalls. RESULTS: Immunophenotypic aberrancy can be construed as a direct expression of the neoplastic phenotype, in contrast to clonal expansion, which is seen in reactive and neoplastic T-cell proliferations. Major and minor T-cell subsets show characteristic patterns of antigen expression. Reactive states can manifest expansions of normal minor subsets and also show alterations of antigen expression on certain populations. However, some patterns of antigen expression are either never or very rarely encountered in reactive T cells. Flow cytometric tools are now available to directly assess clonality in specific T-cell populations. Technical and biological pitfalls may complicate the interpretation of T-cell flow cytometry. CONCLUSIONS: Flow cytometry is a very useful tool in the diagnostic armamentarium for the assessment of mature T-cell proliferations, but it must be interpreted based on a thorough knowledge of the T-cell immune response, as well as an awareness of clinical context.


Sujet(s)
Lymphomes , Prolifération cellulaire , Cytométrie en flux/méthodes , Humains , Immunophénotypage , Lymphomes/diagnostic , Sous-populations de lymphocytes T
3.
Leuk Res Rep ; 17: 100329, 2022.
Article de Anglais | MEDLINE | ID: mdl-35651540

RÉSUMÉ

OBJECTIVE/BACKGROUND: Low risk myelodysplastic syndrome (MDS) is a marrow failure state eventually leading to transfusion dependence. Flow cytometry has previously been demonstrated as prognostic tool in MDS, however not thoroughly studied in lower risk MDS. In this study, we assessed whether assessment for immunophenotypic blast aberrancies by flow in low risk MDS patients has a prognostic role in these patients. METHODS: A total of 63 consecutive patients diagnosed with low/intermediate risk MDS were included. We recorded initial flow results, and collected time to transfusion dependence, and AML progression. RESULTS: On multivariate cox regression analysis, increasing IPSS-R score, an increase in the number of blast aberrancies on flow cytometry, and aberrant expression of CD7 on myeloid blasts increased likelihood of transfusion dependence. CONCLUSION: Low risk MDS patients with increasingly aberrant blast phenotypes by flow may be at risk for earlier transfusion dependence.

5.
J Cutan Pathol ; 48(5): 706-712, 2021 May.
Article de Anglais | MEDLINE | ID: mdl-33476057

RÉSUMÉ

Solid organ and hematopoietic stem cell transplantation may be complicated by the development of post-transplant lymphoproliferative disorders (PTLDs). The World Health Organization categorizes PTLDs into four entities including non-destructive, monomorphic, polymorphic, and classical Hodgkin lymphoma types. The most common PTLDs are B-cell lymphomas, with T-cell lymphomas accounting for only a few cases. Cutaneous T-cell lymphomas are rarer still in post-transplant patients with primary cutaneous peripheral T-cell lymphoma being an extraordinarily rare subtype in this population. PTLDs may be aggressive and are often associated with high morbidity and mortality. Advances in medicine have led to increased awareness of PTLDs and improved diagnostic tools which assist in the diagnosis of these conditions. However, the clinical and histopathologic heterogeneity of PTLDs may make diagnosis a challenge. In the transplant patient population, the cutaneous manifestations of the lymphoproliferative disease may mimic other conditions, such as eczematous dermatitis and graft-vs-host disease. Herein, we report a case of post-transplant primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) in a pediatric heart transplant patient and describe the clinical presentation and diagnostic histopathologic features.


Sujet(s)
Transplantation cardiaque/effets indésirables , Lymphome T cutané/anatomopathologie , Lymphome T périphérique/anatomopathologie , Syndromes lymphoprolifératifs/anatomopathologie , Adulte , Autogreffes , Biopsie , Antigènes CD3/immunologie , Chimioradiothérapie/méthodes , Enfant d'âge préscolaire , Diagnostic différentiel , Eczéma/diagnostic , Eczéma/anatomopathologie , Femelle , Maladie du greffon contre l'hôte/diagnostic , Maladie du greffon contre l'hôte/anatomopathologie , Transplantation de cellules souches hématopoïétiques , Humains , Immunohistochimie/méthodes , Lymphadénopathie/complications , Lymphadénopathie/métabolisme , Lymphome T cutané/diagnostic , Lymphome T cutané/immunologie , Lymphome T cutané/thérapie , Lymphome T périphérique/complications , Syndromes lymphoprolifératifs/étiologie , Mâle , Adulte d'âge moyen , Neutropénie/sang , Récidive , Peau/anatomopathologie , Tumeurs cutanées/anatomopathologie
6.
Leuk Lymphoma ; 62(1): 158-166, 2021 01.
Article de Anglais | MEDLINE | ID: mdl-32951486

RÉSUMÉ

We compared the outcomes of salvage chemotherapy in 146 patients with relapsed (57.5%) or refractory (42.5%) AML who received CLAG-M (51%), MEC (39%) or CLAG (10%). Minimal residual disease (MRD) was assessed by flow cytometry. Bivariate, Kaplan-Meier, and Cox regression analyses were conducted. Complete remission (CR) rate of 46% (CLAG-M 54% versus MEC/CLAG 40%, p = .045) was observed with MRD-negative CR of 33% (CLAG-M 39% versus MEC/CLAG 22%, p = .042). Median overall survival (OS) was 9.7 months; the longest OS occurred with CLAG-M (13.3, 95%CI 2.4-24.3) versus MEC (6.9, 95%CI 2.9-10.9) or CLAG (6.2, 95%CI 2.4-12.6) (p = .025). When adjusted for age, gender, relapsed/refractory AML, poor risk AML, MRD, chemotherapy and transplant, CLAG-M (HR 0.63, 95% CI 0.40-0.98, p = .042), MRD-negativity (HR 0.15, 95% CI 0.07-0.30, p < .001) and transplant (HR 0.22, 95% CI 0.13-0.39, p < .001) were associated with higher OS. Our findings confirm that CLAG-M is a reasonable salvage regimen for RR-AML followed by transplant.


Sujet(s)
Cytarabine , Leucémie aigüe myéloïde , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Chloro-2 désoxyadénosine/usage thérapeutique , Cytarabine/usage thérapeutique , Humains , Leucémie aigüe myéloïde/diagnostic , Leucémie aigüe myéloïde/traitement médicamenteux , Maladie résiduelle , Pronostic , Induction de rémission , Thérapie de rattrapage
7.
Am J Clin Pathol ; 153(2): 181-189, 2020 01 02.
Article de Anglais | MEDLINE | ID: mdl-31602457

RÉSUMÉ

OBJECTIVES: The naming convention in coagulation may cause confusion in electronic ordering systems, leading to inappropriate test orders. We implemented test utilization efforts and studied utilization before and after interventions for two specialty coagulation assays. METHODS: Two interventions were implemented: test names were changed from factor assay to activity, and residents reviewed all factor V and X requests. A retrospective review of factor V and X activity orders was performed for the period 1 year before and after interventions. RESULTS: After interventions, factor V and X activity orders decreased by approximately 40%. Resulted tests decreased by 53.8% and 47.8%, corresponding to reductions of $2,493.05 and $1,867.80 per year in laboratory charges for factor V and factor X activity, respectively. Abnormal factor V activity results increased from 45% to 59%. Factor V activity orders from outpatient clinics decreased by 21.6%. CONCLUSIONS: Simple interventions can reduce inappropriate specialty coagulation test orders and unnecessary costs.


Sujet(s)
Tests de coagulation sanguine/statistiques et données numériques , Techniques de laboratoire clinique/statistiques et données numériques , Proaccélérine/analyse , Facteur X/analyse , Tests de coagulation sanguine/économie , Techniques de laboratoire clinique/économie , Proaccélérine/génétique , Inhibiteurs du facteur Xa/sang , Humains , Mutation , Études rétrospectives , Procédures superflues
8.
Arch Pathol Lab Med ; 143(12): 1464-1471, 2019 12.
Article de Anglais | MEDLINE | ID: mdl-31584842

RÉSUMÉ

CONTEXT.­: Large B-cell lymphoma classification has changed significantly over the decades, evolving from a purely morphologic categorization to one using sophisticated ancillary studies including molecular analysis, immunohistochemistry, and cytogenetics, in addition to morphology and clinical presentation. OBJECTIVE.­: To discuss and interpret the key ancillary studies required for subclassification in 2019 and review the differential diagnosis of diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). DATA SOURCES.­: Recent literature on the subcategories of large B-cell lymphoma is reviewed, along with relevant updates from the 2016 World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues, with an emphasis on Epstein-Barr virus-positive lymphoproliferative disorders, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and large B-cell lymphoma with IRF4 rearrangement. CONCLUSIONS.­: Cases with DLBCL, NOS histology can be further subclassified on the basis of cell of origin studies, Epstein-Barr virus-encoded small RNAs, MYC and BCL2 and/or BCL6 rearrangement studies, and other relevant cytogenetic and immunohistochemical studies. The diagnosis of DLBCL, NOS is therefore a diagnosis of exclusion.


Sujet(s)
Lymphome B diffus à grandes cellules/diagnostic , Diagnostic différentiel , Humains , Lymphome B diffus à grandes cellules/classification
9.
Int J Lab Hematol ; 41(1): 69-79, 2019 Feb.
Article de Anglais | MEDLINE | ID: mdl-30216684

RÉSUMÉ

INTRODUCTION: Carcinocythemia is a rare phenomenon defined as morphologically identifiable, circulating tumor cells in the peripheral blood. No modern case series of carcinocythemia exists in the literature. METHODS: Blood smears from carcinocythemia patients were reviewed and associated clinicopathologic findings described and compared to the literature. When available, bone marrows were examined. RESULTS: We identified 7 carcinocythemia cases over 3 years at our institution in 5 females and 2 males with a median age of 57 and compare them to 26 case reports in the literature (19 females, 10 males; median age 57). The primary neoplasms were carcinomas of breast (3 cases), lung, non-small cell (2 cases), prostate (1), and 1 case of unknown primary. Circulating tumor cells were associated with fragmentation hemolysis (2 cases), asplenic RBC changes (3 cases), and myeloid antigen expression by flow cytometry (2 cases) and were most commonly found at the feathered edge of the slide (6 cases) as single cells or in clusters. CONCLUSIONS: This represents the largest series of carcinocythemia reported. The identification of 7 cases at one institution over a 3-year period suggests carcinocythemia may becoming more common. Raising awareness of this entity and its associated clinicopathologic findings may help avoid diagnostic pitfalls in blood smear examinations and may guide timely clinical management.


Sujet(s)
Cellules sanguines/anatomopathologie , Cellules tumorales circulantes/anatomopathologie , Myélogramme , Tumeurs du sein/anatomopathologie , Carcinome pulmonaire non à petites cellules/anatomopathologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Études rétrospectives
10.
Am J Clin Pathol ; 148(6): 485-493, 2017 Nov 20.
Article de Anglais | MEDLINE | ID: mdl-29126177

RÉSUMÉ

OBJECTIVES: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40% of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling. METHODS: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs. RESULTS: We found that 26 (79%) of 33 PTLDs were CD30+. Of these, 17 (77%) of 22 DLBCL monomorphic PTLDs were CD30+ compared with 56 (38%) of 148 de novo DLBCLs (P = .009). The median FoxP3+ Treg count was higher in CD30+ than in CD30- PTLDs, 3.0 vs 0 (P = .012). CONCLUSIONS: These findings suggest a pathophysiologic link between CD30 activity and Tregs and may indicate differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.


Sujet(s)
Antigènes CD30/métabolisme , Lymphome B diffus à grandes cellules/anatomopathologie , Syndromes lymphoprolifératifs/métabolisme , Lymphocytes T régulateurs/métabolisme , Adulte , Sujet âgé , Infections à virus Epstein-Barr/anatomopathologie , Femelle , Humains , Lymphome B diffus à grandes cellules/diagnostic , Lymphome B diffus à grandes cellules/thérapie , Syndromes lymphoprolifératifs/thérapie , Mâle , Adulte d'âge moyen , Seconde tumeur primitive/métabolisme , Seconde tumeur primitive/anatomopathologie , Lymphocytes T régulateurs/anatomopathologie , Jeune adulte
11.
Clin Lab Med ; 37(4): 697-723, 2017 12.
Article de Anglais | MEDLINE | ID: mdl-29128065

RÉSUMÉ

Flow cytometric evaluation is considered a standard ancillary study for the diagnosis of most B-cell lymphoproliferative disorders. Establishing a neoplastic B-cell population depends on identification of light chain restriction or lack of light chain expression in mature neoplasms and demonstration of aberrant antigen expression in both immature and mature neoplasms, as compared with normal counterparts. The immunophenotypes of the most common B-cell neoplasms are herein described, with an emphasis on their immunophenotypic differential diagnosis and prognostic and therapeutic implications.


Sujet(s)
Cytométrie en flux , Lymphome B , Humains , Immunophénotypage , Lymphome B/classification , Lymphome B/diagnostic
12.
Ann Diagn Pathol ; 29: 23-27, 2017 Aug.
Article de Anglais | MEDLINE | ID: mdl-28807337

RÉSUMÉ

OBJECTIVES: CD43 is normally expressed only on the surface of leukocytes, and is considered a sensitive and specific marker for hematologic malignancies. As such, it may have diagnostic utility in confirming hematolymphoid lineage in cases that are negative for CD45. Aberrant CD43 expression has been described in non-hematopoietic tumors, although literature data on this topic is variable and sometimes contradictory. To clarify and expand on existing literature findings, we evaluated CD43 expression by immunohistochemistry (IHC) in a large cohort (307) of non-hematopoietic neoplasms, including poorly differentiated malignancies. METHODS: 17 tissue microarrays and sections from 19 individual cases were stained with CD43 (clone DF-T1) monoclonal antibody. The proportion of positive cells, stain localization (nuclear, cytoplasmic or membranous), and intensity (compared to internal leukocyte controls) were recorded in all cases. RESULTS: There were 98/307 (32%) positive cases, that showed focal weak nuclear staining in 1-25% of cells, including 23/25 (92%) pancreatic ductal adenocarcinomas; 31/34 (91%) breast invasive ductal carcinomas; 13/15 (87%) papillary thyroid carcinomas; 3/4 (75%) follicular thyroid carcinomas; 6/15 (40%) renal cell carcinomas; 9/28 (32%) lung adenocarcinomas; 1/13 (8%) lung squamous cell carcinomas (SCCs); 2/8 (25%) prostate adenocarcinomas; 8/62 (13%) colon adenocarcinomas; and 2/21 (10%) neuroendocrine neoplasms. None of the positive cases demonstrated strong, membranous CD43 expression comparable to that seen in background mature lymphocytes or segmented neutrophils. Negative cases included 11 cervical SCCs, 12 cervical adenocarcinomas, 19 urothelial carcinomas, 10 lung small cell carcinomas, 11 sarcomas, and 19 poorly differentiated carcinomas from various tissue sites. CONCLUSIONS: In our cohort, most non-hematopoietic neoplasms are negative for CD43 expression, with a subset showing focal, weak nuclear positivity. This data indicates that uniform and strong membranous staining appears to be specific to hematopoietic neoplasms.


Sujet(s)
Marqueurs biologiques tumoraux/métabolisme , Antigènes CD43/métabolisme , Tumeurs/métabolisme , Femelle , Tumeurs hématologiques/métabolisme , Tumeurs hématologiques/anatomopathologie , Humains , Immunohistochimie/méthodes , Mâle
13.
Ann Diagn Pathol ; 25: 15-19, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27806839

RÉSUMÉ

OBJECTIVES: Proliferation centers (PCs) are a characteristic finding in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) lymph nodes, and their presence and extent in this site are not currently felt to be related to clinical course. In contrast, detailed clinicopathologic analyses of bone marrow (BM) PCs have not been previously reported. METHODS: The PCs in 88 CLL/SLL BMs from 45 patients (pts) were graded (0-4) and were correlated with other morphologic, immunophenotypic, cytogenetic, and laboratory features. RESULTS: Proliferation centers were present in 69 BMs (78%) from 32 pts (71%) and were distinct/prominent (grades 2-4) in 21 pts (47%), with the latter more commonly found in follow-up BMs (1/7 diagnostic BMs vs 49/81 follow-up BMs; P=.04). When present, PCs were most commonly graded as distinct nodules easily visible on ×10. No relationships were identified between PCs and any complete blood count parameter, serum lactate dehydrogenase or IgG levels, degree or pattern of BM involvement, blood morphology, CD38 and FMC7 expression by flow cytometry, or fluorescence in situ hybridization results, when the first encountered BM was considered for each patient. CONCLUSIONS: This represents the first detailed analysis of PCs in CLL/SLL BMs. In our tertiary center, PCs were seen frequently, in approximately three-fourths of cases. There were no statistical associations identified between PCs and cytogenetic, immunophenotypic, or other laboratory and morphologic findings.


Sujet(s)
Moelle osseuse/anatomopathologie , Prolifération cellulaire/physiologie , Leucémie chronique lymphocytaire à cellules B/anatomopathologie , Noeuds lymphatiques/anatomopathologie , Lymphome B/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Cytométrie en flux/méthodes , Humains , Immunophénotypage , Hybridation fluorescente in situ/méthodes , Lymphome B/diagnostic , Mâle , Adulte d'âge moyen
14.
Am J Clin Pathol ; 146(2): 170-81, 2016 Aug.
Article de Anglais | MEDLINE | ID: mdl-27413139

RÉSUMÉ

OBJECTIVES: We sought to immunophenotype blasts, monocytes, and granulocytes in chronic myelomonocytic leukemias (CMMLs) and compare CMML subtypes, to identify if significant antigen expression differences existed. METHODS: Bone marrow blasts, monocytes, and granulocytes from CMML subgroups (n = 30; World Health Organization types 1/2, proliferative/dysplastic, therapy related/de novo, and low/intermediate/high cytogenetic risk) were immunophenotypically compared by flow cytometry with 10 nonneoplastic control marrows. RESULTS: Aberrancies were present in blasts of 26 (87%) of 30 CMMLs (26 diagnostic; four follow-up) and six (60%) of 10 controls (P = .089), monocytes of 28 (93%) of 30 CMMLs and six (60%) of 10 controls (P = .026), and granulocytes of eight (28%) of 29 CMMLs and zero of 10 controls (P = .166). Underexpression of CD14 and CD15 on monocytes was more common in CMMLs compared with controls (P = .008 and P = .043). Statistical analysis showed no significant difference in antigen expression between the CMML subgroups on blasts or monocytes; granulocytes demonstrated more common HLA-DR expression in CMML-2 vs CMML-1. CONCLUSIONS: These findings confirm heterogeneity within CMML subgroups and find no specific qualitative or quantitative findings characteristic of a subgroup.


Sujet(s)
Immunophénotypage/méthodes , Leucémie myélomonocytaire chronique/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Antigènes CD/analyse , Marqueurs biologiques tumoraux/analyse , Femelle , Cytométrie en flux , Humains , Leucémie myélomonocytaire chronique/classification , Mâle , Adulte d'âge moyen , Facteurs de risque
16.
Clin Lymphoma Myeloma Leuk ; 16(7): 379-86, 2016 07.
Article de Anglais | MEDLINE | ID: mdl-27160644

RÉSUMÉ

BACKGROUND: Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative option for multiple myeloma (MM). We analyzed our experience of allo-HCT in MM and examined outcomes in 77 consecutive patients with MM receiving allo-HCT from matched sibling (n = 69) or unrelated donors (n = 8). The primary objectives were to assess overall survival (OS), progression-free survival (PFS), and non-relapse mortality in these patients. PATIENTS AND METHODS: Sixty-six patients received non-myeloablative/reduced-intensity conditioning regimens, while 11 received myeloablative regimens. The median follow-up of survivors was 50 months (range, 2.3-129.3 months). RESULTS: Twenty-seven (35.1%) patients had high-risk cytogenetics at diagnosis (t (4:14), 17p deletion, chromosome 1 abnormality, or t (14:16)). All of patients except 1 had prior auto transplant. On multivariate analysis, older age (hazard ratio [HR], 1.055; 95% confidence interval [CI], 1.001 = 1.11; P = .04), less than complete remission (CR) at allo-HCT (HR, 4.3; 95% CI, 1.3-14.1; P = .006), and cytomegalovirus reactivation (HR, 3.2; 95% CI, 1.38-7.6; P = .002) were associated with higher mortality risk. Less than CR at allo-HCT was also associated with higher risk for non-relapse mortality (HR, 5.8; 95% CI, 1.3-26.3; P = .02). There was no difference in OS or PFS between high-risk and standard-risk cytogenetics. No difference in OS and PFS was seen in those who had morphological complete response regardless of the minimal residual disease status. CONCLUSION: Allotransplant benefited younger patients and those in CR at the time of transplant. The adverse effect of high-risk cytogenetics may be overcome by the allo-HCT.


Sujet(s)
Transplantation de cellules souches hématopoïétiques , Myélome multiple/thérapie , Adulte , Sujet âgé , Marqueurs biologiques , Aberrations des chromosomes , Évolution de la maladie , Femelle , Études de suivi , Survie du greffon , Maladie du greffon contre l'hôte/étiologie , Maladie du greffon contre l'hôte/prévention et contrôle , Transplantation de cellules souches hématopoïétiques/effets indésirables , Transplantation de cellules souches hématopoïétiques/méthodes , Humains , Immunohistochimie , Mâle , Adulte d'âge moyen , Myélome multiple/diagnostic , Myélome multiple/mortalité , Stadification tumorale , Maladie résiduelle/diagnostic , Modèles des risques proportionnels , Analyse de survie , Donneurs de tissus , Conditionnement pour greffe/méthodes , Transplantation homologue , Résultat thérapeutique , Jeune adulte
17.
Am J Clin Pathol ; 145(4): 538-51, 2016 Apr.
Article de Anglais | MEDLINE | ID: mdl-27124944

RÉSUMÉ

OBJECTIVES: Pure erythroid leukemia (PEL) is an extremely rare entity that may, even more rarely, evolve from a preexisting chronic myeloid neoplasm (CMN); there is minimal literature regarding this latter phenomenon. METHODS: We describe 14 patients with PEL that represented progression from a preexisting myelodysplastic syndrome (MDS, n = 8) or myeloproliferative neoplasm (MPN, n = 6), three of which manifested as erythroblastic sarcoma (EBS), a rare entity. These patients had a highly complex karyotype with prominent clonal evolution and a very aggressive clinical course. RESULTS: Patients with PEL from MDS showed a more rapid progression time to PEL and had lower platelet counts compared with PEL from MPN. No other significant differences were found between the two groups. CONCLUSIONS: These data represent the largest cohort of patients with PEL and an antecedent CMN, as well as the largest series of EBS reported to date, and underscore the unique morphologic, cytogenetic, immunophenotypic, and clinical features of this uncommon entity.


Sujet(s)
Leucémie érythroblastique aigüe/anatomopathologie , Syndromes myéloprolifératifs/anatomopathologie , Adulte , Sujet âgé , Évolution de la maladie , Femelle , Cytométrie en flux , Humains , Immunohistochimie , Mâle , Adulte d'âge moyen
18.
Case Rep Hematol ; 2015: 816565, 2015.
Article de Anglais | MEDLINE | ID: mdl-25922771

RÉSUMÉ

Immunoglobulin-derived light chain amyloidosis can occasionally be associated with localized disease. We present a patient with localized lymph node light chain amyloidosis without an underlying monoclonal protein or lymphoproliferative disorder and review the literature of lymph node amyloidosis discussing work-up and risk factors for systemic progression.

19.
Cancer Treat Res ; 165: 305-27, 2015.
Article de Anglais | MEDLINE | ID: mdl-25655616

RÉSUMÉ

Post-transplant lymphoproliferative disorders (PTLD) are a serious complication after solid organ or allogeneic hematopoietic stem cell transplantation and include a range of diseases from benign proliferations to malignant lymphomas. Risk factors for developing PTLD include Epstein-Barr virus (EBV) infection, recipient age, transplanted organ, type of immunosuppression, and genetics. Uncontrolled proliferation of EBV-infected B cells is implicated in EBV-positive PTLD, whereas the pathogenesis of EBV-negative PTLD may be similar to non-Hodgkin's lymphoma in the general population. The World Health Organization (WHO) classifies PTLD into four categories: early lesions, polymorphic PTLD, monomorphic PTLD, and classical Hodgkin's lymphoma (cHL). Treatment is aimed at cure of PTLD, while maintaining transplanted organ function. However, there are no established guidelines for the treatment of PTLD. Immune suppression reduction (ISR) is the first line of treatment in most cases, with more recent data suggesting early use of rituximab. In more aggressive forms of PTLD, upfront chemotherapy may offer a better and more durable response. Sequential therapy using rituximab followed by chemotherapy has demonstrated promising results and may establish a standard of care. Novel therapies including anti-viral agents, adoptive immunotherapy, and monoclonal antibodies targeting cytokines require further study in the prevention and treatment of PTLD.


Sujet(s)
Transplantation de cellules souches hématopoïétiques/effets indésirables , Syndromes lymphoprolifératifs/diagnostic , Syndromes lymphoprolifératifs/étiologie , Syndromes lymphoprolifératifs/thérapie , Transplantation d'organe/effets indésirables , Anticorps monoclonaux d'origine murine/usage thérapeutique , Antiviraux/usage thérapeutique , Infections à virus Epstein-Barr/complications , Humains , Immunothérapie adoptive , Syndromes lymphoprolifératifs/épidémiologie , Syndromes lymphoprolifératifs/prévention et contrôle , Pronostic , Facteurs de risque , Rituximab
20.
Ther Adv Hematol ; 5(1): 3-12, 2014 Feb.
Article de Anglais | MEDLINE | ID: mdl-24490019

RÉSUMÉ

BACKGROUND: Burkitt lymphoma (BL) is a rare, highly aggressive B-cell malignancy treated most successfully with brief-duration, high-intensity chemotherapeutic regimens. The benefit of the addition of rituximab to these regimens remains uncertain. We sought to examine the effectiveness of chemotherapy with and without rituximab in patients with BL. METHODS: This study is a retrospective cohort study of all adult patients with BL diagnosed and treated with modern, dose-intense chemotherapeutic regimens from 1998-2008 at two tertiary care institutions. All cases were confirmed by application of WHO 2008 criteria by hematopathologists. Medical records were reviewed for patient-, disease-, and treatment- related factors as well as treatment response and survival. Factors associated with survival were analyzed using Cox proportional hazards modeling. RESULTS: A total of 35 patients were analyzed: 18 patients received rituximab with chemotherapy (R-chemo) and 17 received chemotherapy (chemo) alone. The median age was 42 (range 20-74 years); 57% were male; 71% had Ann Arbor Stage IV disease; 33% had central nervous system involvement; 78% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. R-chemo was associated with significantly longer overall survival (OS) than chemo alone (5-year OS 70% and 29%, respectively, p = 0.040). On multivariate regression analysis, poor performance status and central nervous system involvement were associated with poorer survival. CONCLUSIONS: The addition of rituximab to chemotherapy was associated with improved OS in patients with Burkitt lymphoma. Poor performance status and central nervous system involvement were prognostically significant on multivariate analysis.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE